5 Key Takeaways
-
1
The VOYAGER study is a Roche-sponsored noninterventional post-marketing study of faricimab involving over 5,000 participants across 28 countries.
-
2
Imaging data in the VOYAGER study was analyzed using AI-based algorithms, specifically the ROSA algorithm for volumetric analysis.
-
3
Faricimab demonstrated significant reductions in intraretinal fluid, halving it by month 1 in patients with diabetic macular edema.
-
4
Subretinal fluid decreased to almost zero by month 6 in the analyzed subgroup, confirming the efficacy of faricimab in real-world settings.
-
5
The ongoing VOYAGER study aims to provide further insights into faricimab's effects on diabetic macular edema and neovascular AMD.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.